199 related articles for article (PubMed ID: 6633998)
1. Treatment of advanced ovarian malignancy with chemoimmunotherapy using autologous tumor and Corynebacterium parvum.
Gusdon JP; Homesley HD; Jobson VW; Muss HB
Obstet Gynecol; 1983 Dec; 62(6):728-35. PubMed ID: 6633998
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy versus chemoimmunotherapy with levamisole or Corynebacterium parvum in advanced lung cancer.
Chahinian AP; Goldberg J; Holland JF; Reisman A; Jaffrey IS; Mandel EM
Cancer Treat Rep; 1982 Jun; 66(6):1291-7. PubMed ID: 6282455
[TBL] [Abstract][Full Text] [Related]
3. Combination chemoimmunotherapy for extensive non-oat cell lung cancer.
Issell BF; Valdivieso M; Hersh EM; Richman S; Gutterman JU; Bodey GP
Cancer Treat Rep; 1978 Jul; 62(7):1059-63. PubMed ID: 356968
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum.
Bast RC; Berek JS; Obrist R; Griffiths CT; Berkowitz RS; Hacker NF; Parker L; Lagasse LD; Knapp RC
Cancer Res; 1983 Mar; 43(3):1395-401. PubMed ID: 6825108
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy and corynebacterium parvum for induction and maintenance of remission in acute myelogenous leukaemia--a controlled study.
Shetty PA; Pai VR; Jani PH; Antia PK; Shahane AD
Indian J Cancer; 1983; 20(2):119-23. PubMed ID: 6580265
[No Abstract] [Full Text] [Related]
6. Requirements for successful immunotherapy and chemoimmunotherapy of a murine model of ovarian cancer.
Vanhaelen CP; Fisher RI
Cancer Res; 1981 Mar; 41(3):980-3. PubMed ID: 7193085
[TBL] [Abstract][Full Text] [Related]
7. Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum.
Lichtenstein A; Berek J; Bast R; Spina C; Hacker N; Knapp RC; Zighelboim J
J Biol Response Mod; 1984 Aug; 3(4):371-8. PubMed ID: 6541243
[TBL] [Abstract][Full Text] [Related]
8. Corynebacterium parvum and cyclophosphamide as combination treatment for a murine mammary adenocarcinoma.
Purnell DM; Bartlett GL; Kreider JW; Biro TG
Cancer Res; 1977 Apr; 37(4):1137-40. PubMed ID: 844041
[TBL] [Abstract][Full Text] [Related]
9. [Preliminary results of studies of the effect of immunostimulation combined with chemotherapy in patients with ovarian cancer].
Pawlicki M; Majsak T
Ginekol Pol; 1988 Jun; 59(6):358-62. PubMed ID: 3069616
[No Abstract] [Full Text] [Related]
10. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
11. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results.
Bertucci F; Viens P; Delpero JR; Bardou VJ; Faucher C; Houvenaeghel G; Maraninchi D
Bone Marrow Transplant; 2000 Jul; 26(1):61-7. PubMed ID: 10918406
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
[TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy and autologous stem cell transplantation in advanced epithelial ovarian cancer.
Cure H; Legros M; Fleury J; Dauplat J; Condat P; Choufi B; Chollet P; Plagne R
Bone Marrow Transplant; 1996 Sep; 18 Suppl 1():S34-5. PubMed ID: 8899168
[No Abstract] [Full Text] [Related]
14. Effects of dose and schedule of immune stimulant on efficacy of combination Corynebacterium parvum-cyclophosphamide treatment for a murine mammary adenocarcinoma.
Purnell DM; Bartlett GL; Kreider JW
Cancer Res; 1979 Jan; 39(1):1-5. PubMed ID: 761179
[TBL] [Abstract][Full Text] [Related]
15. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
16. Intravenous Corynebacterium parvum: an adjunct to chemotherapy for resistant advanced ovarian cancer.
Rao B; Wanebo HJ; Ochoa M; Lewis JL; Oettgen HF
Cancer; 1977 Feb; 39(2):514-26. PubMed ID: 837334
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of an established rat mammary adenocarcinoma (13762A) with intratumor injection of Corynebacterium parvum.
Kreider JW; Bartlett GL; Purnell DM; Webb S
Cancer Res; 1978 Mar; 38(3):689-92. PubMed ID: 626972
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin, cisplatin, and Corynebacterium parvum in non-small cell bronchogenic carcinoma.
Drapkin R; Bjornsson S; Naeher C; Higby D; Caracandas J; Wallens WT; Kuberka N; Suh K; Siddiqi N; Henderson ES
Cancer Treat Rep; 1980; 64(12):1367-9. PubMed ID: 7193520
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity.
Bast RC; Knapp RC; Mitchell AK; Thurston JG; Tucker RW; Schlossman SF
J Immunol; 1979 Nov; 123(5):1945-51. PubMed ID: 489967
[TBL] [Abstract][Full Text] [Related]
20. Chemoimmunotherapy in the management of primary stage III ovarian cancer: a Gynecologic Oncology Group study.
Creasman WT; Gall SA; Blessing JA; Schmidt HJ; Abu-Ghazaleh S; Whisnant JK; DiSaia PJ
Cancer Treat Rep; 1979 Feb; 63(2):319-23. PubMed ID: 445505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
